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Autophagy is a lysosome-dependant intracellular degradation process that eliminates long-lived proteins as well 
as damaged organelles from the cytoplasm. An increasing body of evidence suggests that dysregulation of this 
system plays a pivotal role in the etiology and/or progression of neurodegenerative diseases including motor 
neuron disorders. Herein, we review the latest findings that highlight the involvement of autophagy in the path- 
ogenesis of amyotrophic lateral sclerosis (ALS) and the potential role of this pathway as a target of therapeutic 
purposes. Autophagy promotes the removal of toxic, cytoplasmic aggregate-prone pathogenetic proteins, en- 
hances cell survival, and modulates inflammation. The existence of several drugs targeting this pathway can fa- 
cilitate the translation of basic research to clinical trials for ALS and other motor neuron diseases. 
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1. Introduction 
 
There is still no effective treatment for amyotrophic lateral sclerosis 
(ALS), a fatal, progressive neurodegenerative disease characterized by 
the selective loss of upper and lower motor neurons (MNs) (Bucchia 
et al., 2015). The degeneration of MNs clinically leads to progressive pa- 
ralysis and early death due to respiratory failure. About 90% of the ALS 
cases are sporadic, while 10% are familial, inherited with an autosomal 
dominant/recessive, or X-linked pattern (Marangi and Traynor, 2015). 
Over 30 causative genes have been identified in familial ALS, however 
only 10% of the sporadic forms present an involvement of those genes 
(Chen et al., 2013; Renton et al., 2014; Marangi and Traynor,   2015). 
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ALS pathology is still not completely understood. Many pathways 
have been suggested to play a role in the disease pathogenesis including 
alteration of protein stability, conformation and degradation, distur- 
bances of RNA metabolism, and axonal transport defects (Bucchia 
et al., 2015). In particular, mutated genes that cause ALS, such as super- 
oxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TARDBP 
encoding for TDP-43), and RNA-binding protein FUS, encode proteins 
that can form aggregates (Al-Chalabi et al., 2012). Indeed, the most fre- 
quent protein cell inclusions detected in the central nervous system 
(CNS) of apparently sporadic patients are TDP-43 positive (Neumann, 
2013). Remarkably, these aggregates are detected both in the presence 
of mutations in TARDBP gene and in other ALS causative genes such as 
C9ORF72, SQSTM1, GRN, VCP, UBQLN2, OPTN, and NIPA1 (Marangi and 
Traynor, 2015). 
Mutant aberrant or misfolded proteins, such as TDP-43 and others, 
aggregates in the cytoplasm, nucleus or extracellular matrix damaging 
the cellular organelles and leading to neuronal dysfunction (Walker 
and LeVine, 2000). The increased amount of misfolded proteins not 
 
. 
  
only induces endoplasmic reticulum (ER) stress and reduces protein 
translation, but it also enhances autophagy. On the other side, impair- 
ment of autophagy in neurons and MNs results in the accumulation of 
aggregate-prone proteins and cell death. 
The first evidence of a link between the dysregulation of autophagy 
and ALS came from the observation that autophagic markers are up- 
regulated in post mortem CNS samples of both ALS animal models and 
patients, suggesting that autophagy impairment could play an impor- 
tant role in motor neuron disease pathogenesis (Morimoto  et  al.,  
2007;  Song et  al., 2012). 
 
2. The autophagic processes in healthy and ALS context 
 
The quality of cellular components and the maintenance of homeo- 
stasis are key points for the healthy survival of neurons in their func- 
tional context. Both the ubiquitin–proteasome system (UPS) and the 
autophagy pathway make essential contributions to the maintenance 
of this homeostasis, the former acting in the ubiquitin-mediated pro- 
cessing and degradation of short-lived intracellular proteins, while the 
latter targets long-lived proteins and damaged organelles from cyto- 
plasm to lysosomes for their digestion (Nijholt et al., 2011). The UPS rec- 
ognizes only ubiquitinated proteins for proteasomal degradation, while 
autophagy, whose steps encompass the sequestration, transport to lyso- 
somes, degradation, and utilization of degradation products, seems to 
be a non-selective elimination system, mediated by a specific organelle 
called “autophagosome”. Macroautophagy, microautophagy and 
chaperone-mediated autophagy are the three kinds of autophagic 
mechanisms currently described (Nikoletopoulou et al., 2015). In 
chaperone-mediated autophagy, the Hsp70 protein holds a central 
role in selection and the presentation of ubiquitinated proteins to spe- 
cific receptors on the lysosome, such as p62/SQSTM1, while in 
microautophagy there is a direct internalization of cellular proteins by 
lysosomes. Macroautophagy (Fig. 1) begins with the fusion of a double 
membrane (phagophore) around cellular compounds that have to be 
discarded, forming a so-called autophagosome when the membrane fu- 
sion is completed. Thereafter, these structures are transported along mi- 
crotubules towards the perinuclear region of the cell to fuse with 
lysosomes, where their content is degraded. 
The essential steps of autophagy involve several autophagy-related 
(ATG) proteins, whose coding genes are highly conserved across 
eukaryotes. 
The pathway modulating autophagy relies on the mammalian target 
of rapamycin complex 1 (mTOR), which inhibits autophagy by phos- 
phorylating proteins such as ULK1, ATG13 and FIP200 that act upstream 
in phagophore formation. 
The elongation of autophagosome is obtained by two conjugation 
steps involving the ATG12–ATG5–ATG16L complex and the phosphati- 
dylethanolamine (PE)–light chain 3 (LC3) system. Microtubule- 
associated protein 1 LC3 is processed by ATG4 to produce cytosolic 
LC3-I, which is conjugated by ATG3 and ATG7 to PE to generate 
membrane-associated LC3-II on autophagosome precursors. 
Ultimately, mature autophagosomes fuse with lysosomes, where hy- 
drolyzing enzymes catalyze the digestion of cellular components. After 
the degradation is completed, membranes assembled in autophagic 
vesicles are returned to cellular membrane and recycled (Rubinsztein 
et al., 2015; Nikoletopoulou et al., 2015). 
Neurons and other long-lived cells rely on the correct activity of both 
ubiquitin and autophagy degradation systems. Knockout mice for sever- 
al ATG genes showed the accumulation of aggregates in the cytoplasm 
and led to neuropathological phenotypes (Hara et al., 2006; Komatsu  
et  al., 2006). 
The survival of MNs turns out to be particularly affected by autoph- 
agy disruption, as recently demonstrated by the experimental data 
(Ferrucci et al., 2011). Cytoplasmic inclusions containing LC3-II and 
p62/SQSTM1, two typical markers of autophagy, were detected in spinal 
MNs of ALS patients suggesting both activation and alteration of au- 
tophagy in the pathogenesis of sporadic ALS (Sasaki, 2011). In physio- 
logic macroautophagy, the delivery of autophagosome to    lysosomes, 
 
 
 
 
Fig. 1. Schematic view of functional autophagy in neurons (upper panel) and impairment of the process at different stages in ALS pathogenesis (lower panels). Accumulation of aggregates 
of proteins involved in familial ALS (SOD1 and TDP-43) within autophagic vesicles is marked in red. Defects of dynein/dynactin complex altering the trafficking of autophagosomes, as well 
as impaired activation of autophagic flux and lysosome function are highlighted (red crosses) as the main processes responsible for autophagy dysfunction in ALS. 
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in order to form an autolysosome, depends on microtubules in a dynein/ 
dynactin-dependent manner (Mizushima, 2007). In the vacuolar mem- 
branes of ALS tissues an abnormal accumulation of lysosome-associated 
membrane proteins (LAMP-1 and LAMP-2) and LC3-I, which are the 
major protein markers of autophagosome, was observed, suggesting 
that immature autophagosomes could be the result of an alteration in 
the final fusion steps between autophagosomes and lysosomes (Tresse 
et al., 2010). Impairment of the retrograde axonal transport in SOD1 
G93A mice may be responsible for the accumulation of autophagosomes 
as a result of a defect in the autophagosome–lysosome fusion, which oc- 
curs mainly in the soma (Nixon, 2007). 
Despite several lines of evidence highlighting the role of autophagy 
in ALS pathogenesis (Chen et al., 2011), knocking-out motor neuron au- 
tophagy proved to be insufficient to cause ALS in mice, whereas the in- 
hibition of the ubiquitin–proteasome system reproduced some 
cytopathological phenotypes of ALS through the disruption of 26S pro- 
teasome subunit (Tashiro et al., 2012). 
Thus, it remains to be better clarified whether autophagy plays a 
pathogenetic or bystander role in ALS. 
 
3. Accumulation of ALS pathogenetic proteins and  autophagy 
 
In ALS, the accumulation of aggregated misfolded proteins, such as 
TDP-43 and SOD1, leads to ubiquitin-containing inclusions in cell bodies 
and axons of MNs (Neumann et al., 2006; Shi et al., 2010). Aggregates in 
turn might cause UPS dysfunction (Crippa et al., 2010a) and compensa- 
tory induction of autophagy (Korolchuk et al., 2010). In spinal MNs from 
animal models of ALS (Li et al., 2008) and in post-mortem samples of 
ALS cases (Sasaki, 2011) the alteration of UPS and activation of autoph- 
agy have been observed (Li et al., 2008; Sasaki, 2011). Without cell divi- 
sion, neurons cannot reduce toxic products by dilution, thus resulting 
more sensitive to the accumulation of cytotoxic proteins. ER stress, 
which can progressively lead to neurodegeneration, is also caused by 
the aggregation of unfolded proteins. A possible protective factor with 
respect to this process is the upregulation of KDEL (Lys-Asp-Glu-Leu 
motif) receptor (KDELR), as it is involved in ER stress and protein quality 
control (Song et al., 2012). 
The relationship between TDP-43 aggregates and autophagy was in- 
vestigated by several groups. Aggregates containing TDP-43 can be in- 
duced by the inhibition of autophagy with 3-methyladenine (3-MA) 
(Wang et al., 2010) and by impairment of endosomal sorting complex 
required for transport (ESCRT) (Filimonenko et al., 2007). Conversely, 
the inhibition of mTOR using rapamycin results in the induction of au- 
tophagy, relocalization of TDP-43 to its proper nuclear compartment 
and reduction of its accumulation, and rescue of mRNA processing 
(Wang et al., 2013). In addition, enhancing autophagic flux through an 
mTOR-independent pathway with trehalose inhibits TDP-43 aggregate 
formation (Gomes et al., 2010). Moreover, autophagy-activating mole- 
cules increase TDP-43 clearance and improve neuronal survival in ALS 
models  (Barmada  et  al., 2014). 
The positive effect of upregulating autophagy in ALS has been pointed 
out in SOD1 models (Hetz et al., 2009; Crippa et al., 2010a). Small heat 
shock protein HspB8 decreases the aggregation and promotes the clear- 
ance of mutant SOD1 in SOD1 G93A mice, with no impact on the turnover 
of the  wild-type  protein  (Crippa  et  al.,  2010a).  The  enhancement  
of macroautophagy, observed in X-box-binding protein-1 (XBP-1) 
knockout mice, where the pathway known as unfolded protein response   
is impaired, led to an increased clearance of mutant SOD1 aggregates in 
spinal cord (Hetz et al., 2009). Similarly, autophagy-linked FYVE protein 
may enhance the autophagic removal of misfolded SOD1 aggregates  
in SOD1 G93A mice (Han et al.,   2015). 
Though SOD1 is primarily a cytosolic protein, its partial deposition in 
the mitochondrial intermembrane space was shown to lead to mito- 
chondrial dysfunction  in  mutant  SOD1  transgenic  mice  (Magrane  
et al., 2009). The presence of damaged mitochondria is a pathological 
common  finding  in  ALS  MNs  that  may  be  associated  to  impaired 
autophagy-lysosomal system. Supporting this hypothesis, autophagic 
vacuoles engulfing damaged mitochondria have been observed along 
motor neuron axons in SOD1 G93A mice (Xie et al., 2015). Interestingly, 
the accumulation of vacuoles was linked to an altered dynein-driven 
retrograde transport of late endosomes, and was rescued by the over- 
expression of snapin which competes with SOD1 in binding dynein. Re- 
markably, this leads to MN survival and amelioration of the ALS disease 
phenotype in SOD1 G93A mice (Xie et al.,  2015). 
Beclin1, a key protein in autophagy regulation, has been observed to 
interact with SOD1 and to promote neurodegeneration in SOD1- 
mutated cells and animal models, as confirmed by an increased life 
span of Beclin1 haploinsufficient/SOD1 transgenic animals, that was ac- 
companied by the up-regulation of p62/SQSTM1 and down-regulation 
of LC3-II (Nassif et al., 2014). 
The dysregulation of autophagy in ALS patients is not limited to TDP- 
43 and SOD1 pathology. 
Impairment of UBQLIN2 is associated to autophagic defects with 
even more evidence. UBQLIN2 encodes a protein that promotes a correct 
identification of ubiquitinated misfolded protein by p62/SQSTM1. Mu- 
tations in UBQLIN2 lead to neurodegeneration altering the autophagic 
process (Deng et al., 2011; Gellera et al., 2013). 
Valosin-containing protein (VCP), an ATP-driven chaperone protein 
involved in autosomal dominant form of ALS (Johnson et al., 2011) pro- 
motes the maturation of ubiquitinated autophagosomes and is likely 
implicated in autophagy and in mitochondrial quality control 
(Yamanaka et al., 2012). VCP binds to ubiquitinated protein aggregates 
and has an important role in the removal of stress granules, dense cyto- 
plasmic protein/RNA aggregates that are usually found in ALS patholog- 
ic tissues (Buchan et al., 2013). An observed consequence of mutated 
VCP is the accumulation of autophagosomes caused by the impairment 
of autophagosome/lysosome fusion (Ju et al., 2009), resulting in vacuole 
formation in the muscle tissues of patients with VCP-associated disease 
(Ju and Weihl, 2010; Weihl, 2006). Alteration of autophagy in VCP- 
related disease has been recently confirmed in neurons differentiated 
from  patient-specific  induced  pluripotent  stem  cells  (iPSCs)  (Dec  
et al., 2014). Increased levels of TDP-43, ubiquitin, LC3 and p62/ 
SQSTM1 have been observed in cells from patients suggesting a link be- 
tween mitochondrial dysfunction and autophagosome formation 
(Nalbandian  et  al., 2015). 
At present, the most common mutation in ALS involves an intronic 
hexanucleotide repeat expansion in C9ORF72 gene (Ratti et al., 2012; 
Renton et al., 2014). Although its pathogenetic mechanism is still un- 
clear, it is remarkable that the protein encoded by C9ORF72 localizes 
with autophagosomes and its function is related to endocytic trafficking 
(Farg et al., 2014). However, the up-regulation of LC3-II, mediated by 
siRNA knockdown of C9ORF72, did not support the role of autophagy 
defect as the key pathogenic event in C9ORF72-associated pathology 
(Farg  et  al., 2014). 
Sequestosome 1 (SQSTM1) may represent another potential link be- 
tween autophagy and ALS, as deletions and point mutations of this gene, 
encoding the ubiquitin-binding protein p62/SQSTM1, have been detect- 
ed in ALS (Hirano et al., 2013; Teyssou et al., 2013). p62/SQSTM1 is a 
scaffold that acts as a mediator between ubiquitinated proteins and 
LC3-II in order to facilitate their removal via the autophagy 
(Matsumoto et al., 2011). Several neurodegenerative diseases present 
aggregates containing p62/SQSTM1 (Laurin et al., 2002). The different 
effects on autophagy exerted by p62/SQSTM1 mutations, which are lo- 
cated across multiple domains of the protein, need further investigation 
(Teyssou et al., 2013). 
Optineurin (OPTN1) is an autophagy adaptor, whose mutations are 
linked to ALS (Maruyama et al., 2010; Del Bo et al., 2011). In addition 
to its roles of degradating foreign pathogens (xenophagy) (Wild et al., 
2011) and binding to protein aggregates (Korac et al., 2013), OPTN1 is 
found in neuronal inclusions of patients affected by ALS and other neu- 
rodegenerative diseases (Schwab et al., 2012; Mori et al., 2012). The role 
of OPTN1 in ALS has been further elucidated by the recent discovery of 
  
loss of function mutations in TBK1 gene in familial ALS cases (Cirulli  
et al., 2015). The interaction between TBK1 and OPTN1 is a key factor 
in autophagy and inflammation (Maruyama et al., 2010; Maruyama 
and Kawakami, 2013; Thomas et al., 2013; Kachaner et  al.,  2012).  
TBK1 enhances the autophagic turnover of bacteria-bound 
ubiquitylated proteins (Wild et al., 2011; Gleason et al., 2011), through 
the phosphorylation of OPTN and SQSTM1 (Morton et al., 2008; Pilli  
et al., 2012) and promoting the interaction of OPTN with LC3. TBK1 
co-localization with OPTN and SQSTM1 within autophagosomes, even 
in cells carrying SOD1, TARDBP and FUS mutation, suggests a still undis- 
closed role of these proteins in aggregate formation in ALS (Keller et al., 
2012). A cargo-specific subtype of autophagy seems to be activated by 
aggregates, thus degradating ubiquitinated proteins through the lyso- 
some (Scotter et al., 2014). The SQSTM1 and OPTN deliver ubiquitinated 
proteins to the autophagosome thanks to their function as cargo recep- 
tors and LC3-interaction region motifs. Additionally, the autophagic 
turnover of damaged mitochondria, involving PARKIN/ubiquitin ligase 
pathway, is prone to OPTN activity (Wong and Holzbaur, 2014). 
Overall, OPTN, SQSTM1, VCP and TBK1 play a critical role in patho- 
logical inclusions and degradation mechanisms. An interesting aspect 
is the selective motor neuron death, caused by alteration of this path- 
way, which spares other cell types. Mutations in OPTN, SQSTM1, or 
TBK1 could be responsible for a deficit in cellular riboproteostasis, due 
to the impairment of autophagic mechanisms (Ramaswami et al., 2013). 
Dynactin 1 (DCTN1), another ALS-causing gene (Puls et al., 2003), 
mediates the transfer of autophagosome within the cell to facilitate fu- 
sion with lysosomes (Jahreiss et al., 2008; Kimura et al., 2008). In Perry 
syndrome, a complex neurodegenerative disease manifesting mainly 
with parkinsonism and caused by specific DCTN1 mutations, autophagic 
impairment is suggested by neuronal aggregates containing p62  in 
autoptic specimens (Farrer et al., 2009). 
Additionally, ALS2/alsin, a guanine nucleotide exchange factor for 
the small GTPase Rab5 mutated in juvenile forms of ALS, is involved in 
endosome fusion. ALS2 loss has recently been demonstrated to aggra- 
vate SOD1 H46R-mediated toxicity by affecting endosome– 
autophagosome trafficking (Hadano  et al.,  2010). 
Overall, a key point to understand the pathogenesis of motor neuron 
disease relies on interactions between ALS mutated genes/proteins and 
perturbation of autophagy. The pathogenetic context within such inter- 
actions that occur is emerging as a pivotal process in ALS and deserves 
further investigation. 
 
4. Autophagy as therapeutic target 
 
Based on the above findings, it has been hypothesized that activation 
of autophagy may serve as a therapeutic target for ALS. Despite the 
growing   evidence   that   supports   this   putative   mechanism,     the 
enhancement of autophagy proved to be insufficient to rescue the phe- 
notype in several studies (Fornai et al., 2008a,b; Zhang et al., 2014), or, 
in some cases, to lead to the worsening of the pathology (Zhang et al., 
2011). Autophagy should be more deeply studied, since its tight regula- 
tion may play an important role in the protection of neurons against 
neurodegeneration in ALS. 
Elimination of damaged mitochondria and aggregated proteins via 
the autophagy was able to slow ALS progression (Crippa et al., 2010b; 
Fornai et al., 2008a; Hetz et al., 2009; Xie et al., 2015). On the other 
hand, a reduction of neuronal loss, even though without a complete res- 
cue of the pathology, can be obtained with the autophagy inhibitor 3- 
MA or knocking-down ATG5 or ATG12 (Wong et al., 2011). This  
would suggest that at least in some cases an excessive activation of    
the autophagy flux might be mainly responsible for cell death (Cherra 
and Chu, 2008; Cheung and Ip, 2009; Scarlatti et al.,   2009). 
A number of potential therapeutic compounds promoting autopha- 
gy via the mTOR-dependent and independent fashion have been identi- 
fied to promote the clearance of ALS protein aggregates in MNs. Table 1 
briefly summarizes autophagy modulation-based therapeutic strategies 
that have been investigated in ALS models. 
Rapamycin, an mTOR dependent inducer of autophagy, has been 
shown to up-regulate autophagy, reducing aberrant protein aggrega- 
tion in ALS (Sarkar et al., 2008; Harrison et al., 2009; Malagelada et al., 
2010; Dehay et al., 2010; Caccamo et al., 2011; Hetz et al., 2009). How- 
ever, rapamycin was demonstrated to worsen motor neuron loss and to 
reduce the survival of SOD1 G93A mice (Zhang et al., 2011) when ad- 
ministrated in advanced stages of the disease, while at early stages it 
may exert positive effects (Zhang et al., 2013). Food restriction, another 
autophagy promoter, demonstrated a potential protective role on SOD1 
G93A mice spinal MNs (Staats et al., 2013). 
Considering the mTOR-independent pathway as a possible target to 
modulate autophagy, lithium has been shown to influence ALS 
progression in SOD1 G93A mice through inhibition of inositol 
monophosphatase and the phosphoinositol cycle. However, these puta- 
tive beneficial effects are still controversial, as demonstrated by several 
published clinical trials (Fornai et al., 2008a,b; UKMND-LiCALS Study 
Group et al., 2013). The compound L-690,330, carbamazepine and 
valproic acid may decrease inositol and inositol triphosphate levels 
(Sarkar, 2013), thus showing neuroprotective effects in neurodegener- 
ative models (Sarkar, 2005; Fornai et al., 2008a; Feng et al., 2008; 
Forlenza et al., 2012). Trehalose and resveratrol have shown an impor- 
tant role in reducing protein aggregation and fostering neuronal surviv- 
al (Gomes et al., 2010; Kim et al.,   2007). 
Trehalose, a disaccharide acting as a chemical chaperone, can pro- 
mote the clearance of several aggregation-prone proteins linked to neu- 
rodegeneration such as α-synuclein, huntingtin and Tau, though its 
mechanism has yet to be fully understood. In a recent study, trehalose 
 
Table 1 
Autophagy-promoting molecules tested for  ALS. 
 
Autophagy 
target 
pathway 
 
Molecule Trial phase Findings References 
TORC1 
inhibition 
Rapamycin   Preclinical stage In immunodeficient ALS mice rapamycin, an MTOR-dependent autophagic activator, prolongs 
survival because it increases autophagy without exerting immunosuppression. The goal should be the 
development of molecules that selectively target autophagy without effects on immune response. 
Staats et al. (2013) 
AMPK 
activation 
Lithium Preclinical/clinical 
stage 
Lithium demonstrates neuroprotective effects in mouse models, influencing disease onset and 
duration and prolonging survival. Lithium delays motor neurons death and gliosis, promotes the 
replacement of damaged mitochondria and the removal of alpha-synuclein, ubiquitin, and SOD1 
aggregates. In humans the disease progression in lithium-treated patients was slower than in 
riluzole-treated ones. 
This double-blind, randomized controlled trial of lithium versus placebo in ALS showed no significant 
results concerning effects of lithium on survival at 18 months. 
Fornai et al. (2008a,b), 
 
 
 
 
 
UKMND-LiCALS Study 
Group et al. (2013) 
AMPK 
activation 
Trehalose Preclinical stage In mouse models trehalose, MTOR-independent autophagic inducer, demonstrates neuroprotective 
properties modifying disease onset and duration. Trehalose protects motor neuron survival, decreases 
aberrant protein aggregation and modulates autophagic pathways. It shows protective effects on the 
mitochondria, skeletal muscle and cell apoptosis. 
Zhang et al. (2014) 
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was demonstrated to reduce SOD1 and p62/SQSTM1 aggregation, as 
well as ubiquitinated protein accumulation, thereby inhibiting the 
pro-apoptotic pathway in SOD1 G93A mice (Zhang et al., 2014). 
Furthermore, resveratrol and curcumin exhibit a neuroprotective ac- 
tivity in models of neurodegenerative disorders, working as indirect 
mTOR-dependent activators of autophagy (Jeong et al., 2012; Jiang 
et al., 2013; Wu et al., 2011). 
Arimoclomol, an inducer of heat shock proteins, increased SOD1 
G93A mice lifespan, delayed disease onset, improved the neuromuscu- 
lar function and increased motor neuron survival, even if administered 
after the symptom onset (Kieran et al., 2004; Kalmar et al., 2008). The 
reduction of ubiquitin-positive aggregates in MNs suggests that 
arimoclomol presents an anti-aggregation activity in this ALS model 
(Kalmar et al., 2008). 
Another aspect that has to be evaluated is that in progressive and 
complex neurodegenerative disorders such as ALS, cell death is not lim- 
ited to neurons, but extends also to non-neuronal cells that interact 
with neurons. The modulation of autophagy and stress responses in as- 
trocytes and other non-neuronal populations may be an effective, com- 
plementary approach in the development of a disease-modifying 
therapy for ALS that deserves further investigation (Finsterwald et al., 
2015). 
In order to maintain neuronal and motor neuronal integrity, an equi- 
librium between the formation and degradation of autophagic vacuoles 
should be maintained. This balance is typically lost in the pathologic 
context, manifesting in the overproduction or accumulation of autoph- 
agic vesicles. In this regard, possible therapeutic approaches may induce 
the up-regulation of proteins related to autophagosome maturation, 
such as those involved in endosomal fusion and multivesicular body for- 
mation, counteracting their physiological loss due to aging. Sasaki 
(2011) hypothesized that in the early phase of motor neuron disease, 
the autophagosome–lysosome fusion or the degradation ability of lyso- 
somes may display a normal function, justifying an early therapeutic in- 
tervention through moderate activation of autophagy aimed to reduce 
protein aggregation in MNs. Conversely, at advanced disease stages, 
the disruption of the autophagic flux is responsible for the increase of 
autophagosome production, with the release of lysosomal enzymes 
that further induce cell death and accelerate the pathological process 
(Massey et al., 2006). The mechanisms involved in the switch in autoph- 
agy between early and late ALS phases are not fully understood and 
need further investigation. From this perspective, it is important to de- 
termine the role of aging in the clearance of autophagosomes, since 
ALS typically occurs in late adulthood. 
Given these premises, at early ALS phases, therapeutic enhancement 
of autophagy may aid in re-establishing this autophagic balance. On the 
contrary, augmenting the autophagic process at later disease phases, 
when lysosomal function is less efficient, may be less beneficial, due to 
an increase in autophagosome synthesis that overwhelms the clearance 
capacity of lysosomes (Bové et al., 2011). 
 
5. Conclusions 
 
An increasing body of evidence points to a central role of autophagy 
in motor neuronal function and pathology. Intracellular autophagy is 
the major process for the degradation of abnormal protein aggregates, 
which are hallmarks of familial and sporadic ALS. Impairment in au- 
tophagy is present in degenerating MNs, although the direct link be- 
tween autophagy disruption and cell loss remains to be fully 
undisclosed. Nevertheless, experimental  data suggest  the enhancement 
of autophagy as a possible therapeutic strategy for ALS. At this early 
stage of research, testing known compounds that act on the autophagy 
(Table 1) is increasing the knowledge on the possible therapeutic effect  
to target this pathway in ALS. Several autophagic inductors such as 
rapamycin, lithium, and trehalose are expected to exert a positive effect 
on ALS, however the findings of possible negative effects in experimen- 
tal models suggest caution in clinical  translation. 
A known critical issue in this field of research is the transition from 
in vitro and in vivo models to humans. Currently available ALS models 
do not entirely recapitulate the human pathology, thus raising the ques- 
tion whether screening therapeutic compounds in such models may 
prove beneficial in humans. In this regard, the advent of iPSC-based 
models may represent a valuable approach for future research 
(Faravelli et al., 2014). 
Further studies to unravel the impact of autophagy in ALS pathogen- 
esis and to elucidate the role of the interaction between proteins in- 
volved in ALS and the autophagic pathway will accelerate the 
discovery and development of effective therapies for motor neuron 
diseases. 
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